565 related articles for article (PubMed ID: 23378344)
21. FOXC2 expression and epithelial-mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer.
Børretzen A; Gravdal K; Haukaas SA; Beisland C; Akslen LA; Halvorsen OJ
J Pathol Clin Res; 2019 Oct; 5(4):272-286. PubMed ID: 31464093
[TBL] [Abstract][Full Text] [Related]
22. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
Geng S; Guo Y; Wang Q; Li L; Wang J
Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
[TBL] [Abstract][Full Text] [Related]
23. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1α expression in third-sphere forming breast cancer stem cell-like cells.
Han M; Wang Y; Liu M; Bi X; Bao J; Zeng N; Zhu Z; Mo Z; Wu C; Chen X
Cancer Sci; 2012 Jun; 103(6):1058-64. PubMed ID: 22435731
[TBL] [Abstract][Full Text] [Related]
24. Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.
Doherty MR; Cheon H; Junk DJ; Vinayak S; Varadan V; Telli ML; Ford JM; Stark GR; Jackson MW
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13792-13797. PubMed ID: 29229854
[TBL] [Abstract][Full Text] [Related]
25. FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition.
Pietilä M; Vijay GV; Soundararajan R; Yu X; Symmans WF; Sphyris N; Mani SA
Sci Rep; 2016 Apr; 6():23070. PubMed ID: 27064522
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties.
Paranjape AN; Soundararajan R; Werden SJ; Joseph R; Taube JH; Liu H; Rodriguez-Canales J; Sphyris N; Wistuba I; Miura N; Dhillon J; Mahajan N; Mahajan K; Chang JT; Ittmann M; Maity SN; Logothetis C; Tang DG; Mani SA
Oncogene; 2016 Nov; 35(46):5963-5976. PubMed ID: 26804168
[TBL] [Abstract][Full Text] [Related]
27. Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential.
Knezevic J; Pfefferle AD; Petrovic I; Greene SB; Perou CM; Rosen JM
Oncogene; 2015 Dec; 34(49):5997-6006. PubMed ID: 25746005
[TBL] [Abstract][Full Text] [Related]
28. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
[TBL] [Abstract][Full Text] [Related]
29. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells.
Bao B; Wang Z; Ali S; Kong D; Banerjee S; Ahmad A; Li Y; Azmi AS; Miele L; Sarkar FH
J Cell Biochem; 2011 Sep; 112(9):2296-306. PubMed ID: 21503965
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells.
Fan F; Samuel S; Evans KW; Lu J; Xia L; Zhou Y; Sceusi E; Tozzi F; Ye XC; Mani SA; Ellis LM
Cancer Med; 2012 Aug; 1(1):5-16. PubMed ID: 23342249
[TBL] [Abstract][Full Text] [Related]
31. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression.
May CD; Sphyris N; Evans KW; Werden SJ; Guo W; Mani SA
Breast Cancer Res; 2011 Feb; 13(1):202. PubMed ID: 21392411
[TBL] [Abstract][Full Text] [Related]
32. CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression.
Li L; Liu C; Amato RJ; Chang JT; Du G; Li W
Oncotarget; 2014 Nov; 5(21):10840-53. PubMed ID: 25333262
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of epithelial-mesenchymal transition proteins Twist and Foxc2 in phyllodes tumours of the breast.
Lim JC; Koh VC; Tan JS; Tan WJ; Thike AA; Tan PH
Breast Cancer Res Treat; 2015 Feb; 150(1):19-29. PubMed ID: 25677742
[TBL] [Abstract][Full Text] [Related]
34. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties.
Sarrio D; Franklin CK; Mackay A; Reis-Filho JS; Isacke CM
Stem Cells; 2012 Feb; 30(2):292-303. PubMed ID: 22102611
[TBL] [Abstract][Full Text] [Related]
35. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.
Wei L; Liu TT; Wang HH; Hong HM; Yu AL; Feng HP; Chang WW
Breast Cancer Res; 2011 Oct; 13(5):R101. PubMed ID: 22023707
[TBL] [Abstract][Full Text] [Related]
36. Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells.
Jo M; Eastman BM; Webb DL; Stoletov K; Klemke R; Gonias SL
Cancer Res; 2010 Nov; 70(21):8948-58. PubMed ID: 20940399
[TBL] [Abstract][Full Text] [Related]
37. Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer.
Choi J; Park J; Cho I; Sheen Y
Radiol Oncol; 2022 Apr; 56(2):185-197. PubMed ID: 35390248
[TBL] [Abstract][Full Text] [Related]
38. Mitochondrial retrograde signaling induces epithelial-mesenchymal transition and generates breast cancer stem cells.
Guha M; Srinivasan S; Ruthel G; Kashina AK; Carstens RP; Mendoza A; Khanna C; Van Winkle T; Avadhani NG
Oncogene; 2014 Nov; 33(45):5238-50. PubMed ID: 24186204
[TBL] [Abstract][Full Text] [Related]
39. Overexpressed FOXC2 in ovarian cancer enhances the epithelial-to-mesenchymal transition and invasion of ovarian cancer cells.
Liu B; Han SM; Tang XY; Han L; Li CZ
Oncol Rep; 2014 Jun; 31(6):2545-54. PubMed ID: 24700112
[TBL] [Abstract][Full Text] [Related]
40. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
